Introduction {#Sec1}
============

Sarcopenia is a disease that is characterized by the decline of skeletal muscle mass, muscle strength, and physical performance^[@CR1]^. It is associated with the aging process and can lead to significant morbidity and disability in elderly populations, including loss of independence, poor quality of life, and an increased risk of death^[@CR2]--[@CR5]^. The rate of sarcopenia in the elderly is expected to increase in the future^[@CR6]^. This disease contributes to current increased health care costs^[@CR7]^ and is becoming a major public health problem^[@CR8]^. Because of the debilitating symptoms and increased healthcare cost burden, preventing and treating sarcopenia at an early stage is essential.

Many potential mechanisms of sarcopenia have been investigated such as decreased physical activity levels, hormone deficiencies, decreased dietary protein intake, and chronic inflammation accompanied by a production of catabolic cytokines^[@CR9]^. Chronic inflammation and its resultant production of catabolic cytokines remains the most widely reported mechanism of sarcopenia. Chronic inflammation and catabolic cytokine production is a normal phenomenon linked to aging and is the major risk factor for age-related chronic diseases, such as diabetes^[@CR10]^, hypertension^[@CR11]^ and dyslipidemia^[@CR12]^, all of which are well-known risk factors for cardiovascular disease (CVD)^[@CR13]--[@CR15]^.

CVD is the leading cause of death throughout the world and is increasing at an alarming rate in China^[@CR16]^. The prevalence of its associated cardiovascular risk factors (CVRF) has increased exponentially in recent decades. To the best of our knowledge, only a few studies have been conducted to evaluate the association between sarcopenia and CVRF^[@CR17]--[@CR22]^, with no studies using the Asian Working Group for Sarcopenia (AWGS) definition of sarcopenia^[@CR23]^. Of these studies, there were no clear consensus regarding the correlation between sarcopenia and CVRF. One study reported that sarcopenia was closely associated with increased risk factors for CVD^[@CR18]^. Another study found sarcopenia to be weakly associated with predisposing risk factors for CVD in obese postmenopausal women^[@CR20]^. Other papers have investigated the relationship between sarcopenia and components of CVRF, including diabetes, hypertension and dyslipidemia, but the results have not been clear cut. Moreover, few studies have surveyed the comparative significances of these features by the means of structural equation modeling.

Considering the absence of appropriate and consistent evidence regarding the association between sarcopenia and CVRF, it is necessary to study the relationship between sarcopenia and CVRF to improve public health in China, specifically in suburb-dwelling elderly populations. This study is particularly relevant because, as of 2012, more than 70% of Chinese elderly individuals live in suburban areas^[@CR24]^.

Results {#Sec2}
=======

Table [1](#Tab1){ref-type="table"} presents the clinical and anthropometric characteristics of participants by their sarcopenia status. Subjects with sarcopenia had a statistically significant higher age, but lower BMI, ASM, ASM/height^[@CR2]^, gait speed, and grip strength compared with participants without sarcopenia (*P* \< 0.05). Of the female and widowed individuals, the prevalence of illiteracy and smoking was much higher in the study group with sarcopenia compared with those without sarcopenia (*P* \< 0.05). Diabetes was more prevalent in the sarcopenic participants relative to the nonsarcopenic participants (*P* \< 0.05).Table 1Clinical, anthropometric characteristics of study subjects according to the presence of sarcopenia.ParameterNon Sarcopenia (n = 634)Sarcopenia (n = 77)*P*-valueAge (y)66.33 ± 5.5272.71 ± 7.58 \< 0.001Male, n (%)320(50.5%)29(37.7%)0.040BMI (kg/cm^2^)25.55 ± 3.4622.35 ± 2.91 \< 0.001ASM (kg)19.66 ± 4.3014.17 ± 3.36 \< 0.001ASM/Height^2^ (kg/cm^2^)7.21 ± 0.975.67 ± 0.93 \< 0.001Grip strength (kg)28.39 ± 9.0919.45 ± 6.19 \< 0.0014-meter walking test (m/s)1.02 ± 0.190.83 ± 0.19 \< 0.001IPAQ (Met/wk)2079(865--2079)1680(1826--3272)0.083Widowed, n (%)83(13.1%)28(36.4%) \< 0.001Living alone, n (%)90(14.2%)16(20.8%)0.126Illiteracy, n (%)131(20.7%)30(39.0%)0.001Farming, n (%)534(84.2%)69(89.6%)0.214Smoking, n (%)0.020  Never304(47.9%)24(31.2%)  Former117(18.5%)18(23.4%)  Current213(33.6%)35(45.5%)Alcohol drinking, n (%)0.421  Never or Former383(60.4%)52(67.5%)  \<7 d/wk84(13.2%)7(9.1%)  Daily167(26.3%)18(23.4%)CVRF  Diabetes, n (%)62(9.8%)18(23.3%) \< 0.001  Hypertension, n (%)267(42.1%)36(46.8%)0.437  Dyslipidemia, n (%)186(29.3%)25(32.5%)0.570ASM, appendicular skeletal muscle mass; BMI, body mass index; IPAQ, international physical activity questionnaire; Met/wk, metabolic equivalent task minutes per week; CVRF, cardiovascular risk factors.

The associations between the different CVRF components and sarcopenia are presented in Table [2](#Tab2){ref-type="table"}. After adjusting for covariates in Models 1--3, the CVRF components, including diabetes and hypertension (but not dyslipidemia), were found to be significantly associated with sarcopenia (*P* \< 0.05). The OR and 95% CI in the adjusted model 3 for the factors that were statistically significantly associated with sarcopenia were 2.66(1.41--5.01) for CVRF, 4.55(2.19--9.47) for diabetes and 1.82(1.02--3.27) for hypertension.Table 2Multiple logistic regression analysis of presence and components of CVRF for elderly patients with sarcopenia.VariablesUnivariateModel 1Model 2Model 3CoefficientsR2OR (95%CI)*P*-valueCoefficientsR2OR (95%CI)*P*-valueCoefficientsR2OR (95%CI)*P*-valueCoefficientsR2OR (95%CI)*P*-valuePresence of CVRF0.4240.0081.53(0.92--2.55)0.1050.9030.3572.47(1.33--4.57)0.0040.9060.3592.47(1.34--4.58)0.0040.9780.3682.66(1.41--5.01)0.003**Components of CVRF**Diabetes1.0350.0292.82(1.56--5.07)0.0011.3810.3673.98(1.94--8.17)\<0.0011.4070.3714.08(1.98--8.41)\<0.0011.5150.3804.55(2.19--9.47)\<0.001Hypertension0.1880.0021.21(0.75--1.94)0.4730.5440.3441.72(0.97--3.05)0.0620.5400.3471.72(0.97--3.04)0.0640.5980.3541.82(1.02--3.27)0.046Dyslipidemia0.1470.0011.16(0.70--1.92)0.5700.3850.3401.47(0.81--2.68)0.2090.3850.3431.47(0.80--2.69)0.2110.3750.3481.45(0.79--2.66)0.225Notes: Model 1: adjustment for age, gender, and BMI; Model 2: Model 1+adjustment for marital status, educational level; Model 3: Model 2+adjustment for smoking, IPAQ, and peptic ulcer.

The outcomes of the applications of the models that tested the effects of the increasing numbers of CVRF constituents on sarcopenia are illustrated in Table [3](#Tab3){ref-type="table"}. There was a significant linear decrease in the risk of sarcopenia with an increasing numbers of CVRF constituents. After further covariate adjustment in Model 3, the OR and 95% CI of sarcopenia participants with 1, 2, and 3 features of CVRF were 2.27(1.14--4.48), 4.13(1.80--9.46), and 4.90(1.01--23.81) (*P* values for the trends \< 0.001), respectively. The prevalence of sarcopenia increased steeply with numbers of CVRF (Fig. [1](#Fig1){ref-type="fig"}). Finally, we assessed the performance and calibration of all models. Model performance and calibration were consistently good in all models (Area under the ROC curves \> 0.80; Hosmer-Lemeshow goodness of fit *P* \> 0.05).Table 3Regression analysis of number of CVFR for elderly patients with sarcopenia.Number of CVRFUnivariateModel 1Model 2Model 3CoefficientsOR (95%CI)*P*-valueCoefficientsOR (95%CI)*P*-valueCoefficientsOR (95%CI)*P*-valueCoefficientsOR (95%CI)*P*-value10.3071.36(0.78--2.38)0.2830.7492.12(1.09--4.12)0.0280.7492.11(1.09--4.12)0.0280.8142.27(1.14--4.48)0.02020.5791.78(0.92--3.47)0.0891.3303.78(1.68--8.49)0.0041.3453.84(1.71--8.62)0.0011.4184.13(1.80--9.46)0.00131.1373.12(0.95--10.25)0.0611.4324.19(0.85--20.68)0.0791.4304.18(1.05--20.63)0.0491.5884.90(1.01--23.81)0.041*R2*0.0140.3630.3670.376*P* for trend \< 0.026 \< 0.001 \< 0.001 \< 0.001Notes: Model 1: adjustment for age, gender, and BMI; Model 2: Model 1+adjustment for marital status, educational level; Model 3: Model 2+adjustment for smoking, IPAQ and peptic ulcer. Figure 1Prevalence of sarcopenia with respect to the number of CVRF.

Discussion {#Sec3}
==========

In the present study, we examined the effects of the prevalence of different numbers of CVRF components on sarcopenia using the AWGS definition in suburb-dwelling populations of elderly persons aged 60 and older in China. We found that the prevalence of sarcopenia was significantly proportional to the number of CVRF components. In particular, diabetes and hypertension were significantly associated with a higher risk of sarcopenia in the adjusted models. To our knowledge, our study is the first study that uses the AWGS definition to demonstrate a positive correlation between the prevalence of sarcopenia and CVRF constituents in China.

The major purpose of this study was to test the hypothesis that sarcopenia is associated with CVRF independent of other confounding factors in elderly Chinese populations. With similar findings to our study, a recent study by Kim *et al*.^[@CR18]^ showed that sarcopenia was closely associated with increased risk factors of CVD. However, another study found that sarcopenia seems to be associated with lower risk factors of CVD in obese, postmenopausal women^[@CR20]^. These conflicting results are likely due to the variable limitations related to the assessment of sarcopenia and CVRF, the differences between study populations, and varying ethnic characteristics. Asians have different CVD patterns compared to Caucasians. Koreans immigrants to the United States have significantly higher rates of stroke and lower rates of heart disease compared to Caucasians born in the United States^[@CR25]^. Moreover, Asians have a higher risk for diabetes at a lower BMI compared to Europeans^[@CR26]^, which means that diabetes and its related CVD risks might be different between these two populations. In particular, the results of the present study may be beneficial for further research on the relationship between sarcopenia and CVRF in elderly Chinese populations, which has not been previously studied.

In the present study, diabetes was associated with an elevated risk of sarcopenia, independently of age, gender, BMI, marital status, educational level, and smoking. This result was consistent with the results of previous studies^[@CR10],\ [@CR27]^. Kim *et al*.^[@CR10]^ also reported that diabetes was associated with an increased risk of sarcopenia. Leenders *et al*.^[@CR28]^ found that both appendicular skeletal mass and leg extension strength was lower in individuals with type 2 diabetes mellitus compared with normoglycemic controls. The mechanism of diabetes and its association with accelerated reduction of muscle mass and strength remains unclear. However, it has been reported that diabetes accelerates the loss of muscle mass and strength due to hyperglycemia, insulin resistance, endocrine changes, or the release of inflammatory cytokines^[@CR29]^. Chronic hyperglycemia increases advanced glycation end products (AGEs). AGEs accumulate in skeletal muscle and cartilage and increase stiffness in patients with diabetes. It was reported that elevated AGEs were associated with poor grip strength in older women with moderate to severe disability and slow walking speed in older community-dwelling adults^[@CR30],\ [@CR31]^. Furthermore, inflammatory cytokines, such as tumor necrosis factor and interleukin 6, have detrimental effects on muscle mass, strength, and physical performance in older adults^[@CR32]^. Based on the above, we postulate that diabetes impairs muscle mass, strength, and physical performance which leads to sarcopenia. These findings highlight the importance of diabetes management in the prevention of the onset of sarcopenia.

In this study, although univariate analysis showed no correlation between sarcopenia and hypertension, a multivariate statistical analysis revealed that hypertension was the 2nd most significant feature that was associated with sarcopenia after adjusting for the confounding factors age, gender, BMI, marital status, educational level, and smoking, which is consistent with previous findings^[@CR11]^. To investigate whether sarcopenia is associated with hypertension, Han *et al*.^[@CR11]^ surveyed 2,099 males and 2,747 females in older Koreans, and found that subjects with sarcopenia had a higher prevalence of hypertension than subjects without sarcopenia. The research on the relationship between of sarcopenia with hypertension is very few and limited, and the underlying mechanism that links sarcopenia and hypertension remains unclear. We hypothesize that during the aging process, mast cells, and inflammatory agents such as cytokines (e.g. TNF-alpha), advanced glycosylation products, and matrix metalloproteinases, appear to be related to a state of chronic low-grade inflammation. Recent studies have suggested that these inflammatory agents impair blood flow by damaging the microvascular endothelium^[@CR11]^. As previously mentioned, inflammatory cytokines have detrimental effects on the bodies of older adults and may contribute to sarcopenia. Further studies are warranted to elucidate the causal relationship between hypertension and sarcopenia.

Only a few studies have reported the association between sarcopenia and dyslipidemia in Asia^[@CR12],\ [@CR33]^. Our study showed that there was no correlation between dyslipidemia and sarcopenia. However, in Baek *et al*.^[@CR33]^ study, they investigated the association between sarcopenia and dyslipidemia in elderly Koreans and found that sarcopenia was associated with an increased risk for dyslipidemia. Besides, in a 4-year longitudinal study of 538 elderly Japanese, Kim *et al*.^[@CR12]^ also found dyslipidemia was associated with sarcopenia. The literature regarding sarcopenia and dyslipidemia is few and complex. These contradictory results are likely due to variable susceptibilities related to studied population. In our study, we examined the relatively healthy participants with excluding patients of CVD; Baek *et al*. and Kim studied participants with general population. The studied populations of these researches vary greatly and cause a wide variation in the rate of sarcopenia^[@CR34]^. Besides that, this confounding may also due to different proportions of patients receiving treatment is possible. Statin cholesterol lowering agents are known to have immunomodulatory effects, including inhibiting inflammation^[@CR35]^. However, as already stated, inflammation is associated with increased risk of muscle mass and strength loss and cause sarcopenia. So, there is reason to suspect that statin cholesterol lowering agents may offset some of the dyslipidemia effects on sarcopenia. Thus, disparate results could occur if statin use varied between cohorts.

To our knowledge, the majority of studies have only focused on each individual component of CVRF: diabetes, hypertension and dyslipidemia. There is limited information on the association between the totality of CVRF components and the prevalence of sarcopenia. We note a positive correlation between the prevalence of sarcopenia and the increasing numbers of CVRF constituents. Although there is no previous research showing significant evidence between sarcopenia and the increasing total number of CVRFs directly, Brinkley *et al*.^[@CR36]^ analyzed associations between physical function and inflammatory biomarkers in older adults across multiple comorbidities. Brinkley *et al*. demonstrated that elevated CRP and IL-6 levels are associated with poorer physical function in older adults with various comorbidities. Therefore, we believe the presence of comorbid diseases, such as diabetes, hypertension and dyslipidemia, elevate CRP and IL-6 levels and contribute to sarcopenia.

This study has a number of strengths. First, this study is one of the first studies using the AWGS criteria to identify the correlation between the prevalence of sarcopenia and CVRF constituents. Secondly, the study is also the first study to examine a uniquely defined group: suburban older men and women living in a discrete geographical area. Our participants were recruited from a suburban area and were leading a more physically active lifestyle, which may differ from subjects in other geographical areas.

Despite our efforts, some limitations exist. First, this study used a cross-sectional design, so it is not possible to determine causal relationships. Second, all participants in the present study were relatively healthy as we did not include participants who were unable to participate in the free annual national physical examination (i.e., those bedridden or with serious diseases). Due to these exclusions, our results might in fact underestimate the prevalence of sarcopenia and its associated health impact. A longer follow-up period with higher total number of CVD risk factors may provide a more definitive answer. Third, the self-reported variables may influence the precision of estimation. But similar to our study, some previous studies also collected the data by participants' self-reporting. Thus, we suggest that it would not overturn the findings observed in our study. At last, the use of BIA for muscle mass assessment presents a drawback mainly due to hydration problems often observed in older persons---these may result in an underestimation of body fat and an overestimation of fat-free mass. BIA is not good standard, but it is well correlated with magnetic resonance imaging predictions and DXA. Besides, BIA is inexpensive, rapid, noninvasive, radiation-free, and convenient and is thus considered to be a portable alternative to DXA.

Conclusion {#Sec4}
==========

In summary, we examined the associations between sarcopenia, each individual CVRF component, the total number of CVRF components in Tianjin, China, using the AWGS definition. We found that sarcopenia is independently associated with CVRF and in particular is associated with diabetes and hypertension. The prevalence of sarcopenia increased steeply with an increasing total number of CVRF. Therefore, the prevention and treatment of CVRF may be useful in preventing and delaying the onset of sarcopenia. A further prospective study is needed to establish the causality of CVRF components and sarcopenia.

Methods {#Sec5}
=======

Ethics statement {#Sec6}
----------------

This research was approved by the Ethics Committee at Tianjin Medical University, and the methods were carried out in accordance with the principles of the Declaration of Helsinki. All records were anonymized and no individual information can be identified.

Subjects {#Sec7}
--------

Our study population included residents from three areas: Hougu, East Chadian, and West Chadian of Tianjin, China. A total of 1166 older individuals in these areas joined the national free physical examination program from March 2013 to August 2015; all subjects were invited to participate in a comprehensive geriatric assessment. Of the 1166 subjects aged ≥ 60 years, participants who had previous diagnoses of CVD (i.e., myocardial infarction, coronary insufficiency, stroke, peripheral artery disease, and heart failure) (n = 252) were excluded from the study. Individuals with incomplete anthropometric measurements (n = 52) or laboratory test results (n = 151) were also excluded. A total of 711 subjects (349 men and 362 women) were included in the final statistical analysis. All participants provided informed consent prior to participation.

Questionnaire {#Sec8}
-------------

Data regarding sociodemographic and behavioral characteristics were obtained in a similar manner to our previous studies via face-to-face interactions^[@CR27],\ [@CR37],\ [@CR38]^. Sociodemographic variables, including age, gender, marital status, educational level, and occupation were assessed. The assessed social history included smoking habits (never, former smoker, or current smoker) and drinking habits (never, former drinker, occasional drinker, or everyday drinker). Former smoker and current smokers were asked how many cigarettes they smoke per day and how long they had smoked^[@CR39]^. We next obtained and assessed physical activity levels. The physical activity level was assessed using the short form of the International Physical Activity Questionnaire (IPAQ)^[@CR40]^. A history of physical illness was established using standardized criteria that combined information from a questionnaire regarding history of a physical illness, a physician's diagnosis, and the corresponding medication or current or past medical treatment.

Analysis of blood samples and blood pressure {#Sec9}
--------------------------------------------

A blood sample was obtained from the antecubital vein from patients who fasted overnight for at least 10 h. After collection, samples were centrifuged for 15 min at 3000 rpm. The fasting plasma glucose (FPG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured using the Roche Modular P (Roche Diagnostic Company, Swiss)^[@CR37]^. The systolic blood pressure (SBP) and diastolic (DBP) blood pressure were measured from the upper left arm using a sphygmomanometer after 10 min of sitting^[@CR13]^.

CVD risk factors assessment {#Sec10}
---------------------------

Based on previous research^[@CR41]^, the three CVD major risk factors were defined as follows: diabetes as the use of hypoglycemic agents, a self-reported history of diabetes, or a FPG ≥ 7.0 mmol/L or more^[@CR37]^; hypertension as resting SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or the self-reported current treatment for hypertension with antihypertensive medication^[@CR42]^; dyslipidemia as using lipid-lowering drugs or having one or more of the following: TG ≥ 1.7 mmol/L, TC ≥ 5.18 mmol/L, HDL-C \< 1.04 mmol/L, and LDL-C ≥ 3.37 mmol/L^[@CR43]^.

Assessment of Sarcopenia {#Sec11}
------------------------

Sarcopenia was defined according to the AWGS criteria^[@CR23]^, in which a person who has low muscle mass, low muscle strength, and/or low physical performance was identified as having sarcopenia. Low muscle mass was classified as a relative skeletal muscle mass index (ASM/height^2^) less than 7.0 kg/m^2^ and 5.7 kg/m^2^ in men and women, respectively; low muscle strength was defined as a grip strength \< 26 kg or \< 18 kg for males and females, respectively; low physical performance was defined as a walking speed \< 0.8 m/s for both males and females.

Muscle mass was measured using a direct segmental multi-frequency bioelectrical impedance analysis (BIA) (In-Body720; Biospace Co., Ltd,Seoul, Korea). Muscle strength was assessed by grip strength, measured using a dynamometer (GRIP-D; Takei Ltd, Niigata, Japan). Usual walking speed (m/s) on a 4-meter course was used as an objective measure of physical performance. Details of measurement methods have been described in our previous cross-sectional study^[@CR27]^.

Statistical analysis {#Sec12}
--------------------

Physical activity levels were reported as medians ± 25--75th percentiles for IPAQ; all other continuous variables were presented as means ± SD; classification variables were reported as percentages. Differences in baseline characteristics according to sarcopenia status were analyzed using t-tests, Pearson's chi-square test, and Kruskal--Wallis rank tests. The associations between sarcopenia and CVRF were determined by analyzing each individual CVRF component or the total number of CVRF components. The simple logistic regression analysis was used to examine the independent influence of CVD risk factors on sarcopenia; the odds ratio (OR) and 95% (Confidence Interval, CI) were computed. In addition, adjustments for potential confounders such as age, gender, and BMI (model 1), marital status and educational level (model 2), and smoking, IPAQ, and peptic ulcer (model 3) were performed using multiple logistic regression analyses (Wald backward stepwise method). Analyses were repeated to determine the effect of individual CVRF components on sarcopenia components. The analysis generated regression coefficients, confidence intervals, Nagelkerke R2. Besides, the area under the receiver operating characteristic (ROC) curve and the Hosmer-Lemeshow goodness of fit statistic were calculated to assess the performance and calibration of the model, respectively. The *P*-values for the trend tests were determined by treating the number of CVRF components as a continuous variable (1--3) in order to observe the associations between an increase in the number of CVRF components and sarcopenia. All the statistical analyses were performed using SPSS version 19.0, and P-values less than 0.05 were considered statistically significant.

Peipei Han and Hairui Yu contributed equally to this work.

**Publisher\'s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors thank Guiyan Shao from the Chadian public health center and Xiaofang Ren from Hangu welfare house for providing place and organization. This work was supported by the National Natural Science Foundation of China \[grant numbers 81372118\] and Tianjin Municipal Science and Technology Commission \[grant numbers 16ZXMJSY00070\].

P.H. wrote the main manuscript text. Q.G. conceived and designed research, K.N. analyzed the data. W.Z. and H.Y. discussed the results. Y.M,. L.K., L.F., L.J., H.Y., X.C., X.Y, L.H., and L.W did the most research.

Competing Interests {#FPar1}
===================

The authors declare that they have no competing interests.
